Introduction

White matter abnormalities have been recognized to be associated with aging, geriatric depression and dementia, such as Alzheimer disease (AD).1,2 Furthermore, white matter hyperintensities (WMH) on magnetic resonance imaging (MRI) have been reported to be a risk factor for the conversion from mild cognitive impairment (MCI) to AD.3-5 Even among healthy older people, a significant association between WMH and cognitive dysfunction has been reported, although the reason remains unclear.6,7 Therefore, it is crucial to establish aggressive treatment strategies for the prevention of geriatric syndrome, including dementia and geriatric depression caused by white matter abnormalities. For this, it is very important to assess white matter abnormalities as accurately as possible, and to elucidate the brain mechanisms that are induced by white matter abnormalities from various angles.

Several studies have shown the association between WMH and blood levels of molecules, such as cystatin C (CysC), 25-hydroxyvitamin D and homocysteine, and the presence of lifestyle-associated diseases, such as hypertension, hyperlipidemia and diabetes mellitus.8-10 However, most of these studies have assessed WMH by visual rating, which is not very precise.3-5 In the present study, we calculated the volume of periventricular hyperintensities (PVH) and deep WMH (DWMH) on T2 fluid-attenuated inversion recovery (FLAIR) MRI using 3D Slicer, a freely available, open-source software package for visualization, registration, segmentation, and quantification of medical data (http://www.slicer.org).11 Furthermore, we investigated the association between PVH/DWMH volumes and cognitive function, depressive symptoms, blood levels of various molecules (such as CysC), 25-hydroxyvitamin D and homocysteine) and the presence of lifestyle-associated diseases (such as hypertension, hyperlipidemia and diabetes mellitus) in patients with amnestic MCI.

Methods

Participants

Outpatients (aged >60 years, <90 years) who were enrolled at the memory clinic or outpatient clinic of Tokyo Medical University, Japan.

Aim: White matter hyperintensities (WMH) on MRI have been reported to be a risk factor for the conversion from mild cognitive impairment (MCI) to AD, although the reason remains unclear. In the present study, we hence investigated the associations between WMH volumes and cognitive function, blood levels of various molecules, and the presence of lifestyle-associated diseases in patients with amnestic MCI.

Methods: The initial data of 38 patients with amnestic MCI and 10 normal control individuals were analyzed. The volumes of periventricular hyperintensities (PVH) and deep WMH (DWMH) were measured on T2 fluid-attenuated inversion recovery using the imaging software, 3D Slicer; and the association between PVH/DWMH volumes and cognitive function, blood levels of molecules (such as cystatin C [CysC], 25-hydroxyvitamin D and homocysteine) and the presence of lifestyle-associated diseases (such as hypertension, hyperlipidemia and diabetes mellitus) were analyzed.

Results: In the MCI group, the PVH volume : intracranial volume ratio significantly correlated with Trail Making Test-A/B scores and CysC level by Pearson’s analysis, and the PVH volume : intracranial volume ratio significantly correlated with only CysC levels, whereas the DWMH volume : intracranial volume ratio did not correlate with any items at all by linear multiple regression analysis.

Conclusions: PVH volume was closely associated with frontal lobe dysfunction, particularly with attention and executive dysfunction. Serum CysC level was associated with PVH volume, which suggests that CysC might be a useful marker for determining treatment strategies for white matter abnormalities in amnestic MCI. Geriatr Gerontol Int 2019; 19: 1036–1040.
Tokyo, Japan, were prospectively recruited between 2015 and 2018. Written informed consent was obtained from all participants before the study. The study design was approved by the ethics review board of Tokyo Medical University. Initial data of 38 participants with amnestic MCI and 10 normal control (NC) participants, who were spouses of the MCI patients or who were followed at the outpatient clinic but had no memory complaints, were medically stable and had Mini-Mental State Examination (MMSE) scores of ≥28, were analyzed. All patients underwent detailed general physical, neurological and psychiatric examinations, and extensive laboratory tests, including MRI and single-photon emission computed tomography (SPECT). SPECT images were analyzed using Neurological Statistical Image Analysis software (Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA), which are three-dimensional stereotactic surface projections developed by Minoshima et al. for evaluating the spatial distribution of abnormal perfusion to exclude other potential causes of dementia, including dementia with Lewy bodies, frontotemporal lobar degeneration and so on.12 The reductions in regional cerebral blood flow of the parietotemporal association cortex on SPECT are recognized as a diagnostic pattern of prodromal AD.13

MCI patients were diagnosed as having MCI due to AD according to National Institute on Aging-Alzheimer’s Association criteria, and their MMSE scores were ≥24.14 Individuals were excluded from the study if they did not show any reduction in regional cerebral blood flow in the parietotemporal association areas. Individuals were also excluded if they had territorial or cortical infarctions, or if they showed severe white matter disease in which both PVH and DWMH were grade 3 on the Fazekas scale.15 Cognitive functions and depressive symptoms were assessed by various neuropsychological tests, such as the MMSE, Frontal Assessment Battery, Trail Making Test (TMT)-A/B, Wechsler Memory Scale-Revised-Logical Memory I, verbal fluency and Geriatric Depression Scale-15.

### Laboratory measurements

Serum CysC, 25-hydroxyvitamin D and homocysteine levels were measured using colloidal gold agglutination, radioimmunoassay and high-performance liquid chromatography, respectively. Other laboratory parameters for cerebrovascular risk factors, including total cholesterol, low-density lipoprotein cholesterol, glucose, hemoglobin A1c, vitamin B12, blood urea nitrogen, creatinine, estimated glomerular filtration rate, aspartate transaminase and alanine aminotransferase were measured as well.

### MRI and volumetric analysis

Brain MRI scans (3D-T1 and FLAIR imaging) were carried out using a 1.5-Tesla scanner (Magnetom; Siemens Medical Systems, Erlangen, Germany) with the following parameters: T1 gradient echo images and FLAIR sequences. FLAIR sequences were obtained with the following parameters: slice thickness 4.0 mm; gap 0.0 mm. For quantitative analysis of WMH volumes, FLAIR images were registered. WMH was defined as the observation of hyperintensity in the white matter area. PVH and DWMH lesions were outlined by a neuropsychologist, using the semi-automated freeware, 3D Slicer. Furthermore, intracranial volumes (ICV) were calculated using VBM toolbox, which was implemented in Statistical Parametric Mapping (SPM8; Wellcome Institute of Neurology, University College London, London, UK), and the ratio (%) of PVH and DWMH volume to ICV was used for rating white matter abnormalities.

### Statistical analysis

Demographic and laboratory data were calculated as the mean ± SD. Statistical analyses were carried out using the Student’s t-test, Pearson’s test and linear multiple regression analysis. SPSS 25.0 software (IBM Corporation, Armonk, NY, USA) was used for all statistical analyses.

### Results

A summary of the comparisons of participant characteristics is shown in Table 1. There were significant differences between the MCI group and the NC group with regard to scores on neuropsychological tests, such as MMSE, Frontal Assessment Battery, TMT-B and Geriatric Depression Scale, whereas both PVH and DWMH volumes in the MCI group were greater than in the NC group, although the differences were not statistically significant. Pearson’s analysis showed the correlation of the ratio of PVH and DWMH volume to ICV with continuous variables, including neuropsychological test scores and blood sample data in MCI patients. The PVH volume : ICV ratio significantly correlated with TMT-A/B and CysC levels. Table 2 shows that in MCI patients, CysC levels correlated significantly and positively with the PVH volume : ICV ratio, but not with the DWMH volume : ICV ratio. Table 3 shows the correlations of the ratio of PVH and DWMH volume to ICV with continuous variables and categorical variables, including the presence or not of hypertension, diabetes mellitus, hyperlipidemia, coronary disease and medications (antidiabetes

### Table 1  Demographic, clinical, blood biochemistry and magnetic resonance imaging characteristics of mild cognitive impairment and normal control participants

|                  | MCI (n = 38) | NC (n = 10) |
|------------------|--------------|-------------|
| Sex (male/female)| 13/25        | 5/5         |
| Age (years)      | 77.4 ± 5.6   | 76.5 ± 6.2  |
| Education (years)| 13.4 ± 2.3   | 14.4 ± 1.6  |
| MMSE             | 27.3 ± 1.6*  | 28.7 ± 0.9  |
| FAB              | 13.0 ± 2.2*  | 14.9 ± 2.0  |
| TMT-A (s)        | 52.7 ± 20.8  | 42.2 ± 12.6 |
| TMT-B (s)        | 156.9 ± 80.8*| 102.5 ± 39.6|
| WMS-R-Logical Memory (immediate) | 3.3 ± 0.8 | 3.2 ± 0.3 |
| VF               | 1.0 ± 0.2    | 1.1 ± 0.3   |
| GDS-15           | 2.8 ± 3.1*   | 1.7 ± 1.4   |
| Cystatin C (mg/L)| 25.0 ± 11.9  | 19.9 ± 6.1  |
| Homocysteine (umol/mL) | 10.5 ± 3.5 | 9.4 ± 2.8   |
| PVH volume (mm³) | 8905 ± 7678  | 6175 ± 6253 |
| DWMH volume (mm³) | 4529 ± 9223 | 2777 ± 5154 |
| PVH volume ratio (%) | 0.70 ± 0.60 | 0.45 ± 0.46 |
| DWMH volume ratio (%) | 0.30 ± 0.70 | 0.20 ± 0.37 |
| Hypertension, n (%) | 21 (55)*    | 2 (20)      |
| Diabetes mellitus, n (%) | 7 (18)     | 3 (30)      |
| Hypercholesterol, n (%) | 20 (53)    | 4 (40)      |
| Coronary artery disease, n (%) | 3 (8)     | 1 (10)      |

25(OH)D, 25-hydroxyvitamin D; DWMH, deep white matter hyperintensities; FAB, Frontal Assessment Battery; GDS, Geriatric Depression Scale; MCI, mild cognitive impairment patients; MMSE, Mini-Mental State Examination; NC, normal control participants; PVH, periventricular hyperintensities; TMT, Trail Making Test; VF, verbal fluency; WMS-R-Logical Memory (immediate), Wechsler Memory Scale-Revised-Logical Memory I. *p < 0.05 between the MCI and NC groups.
Table 2  Associations between ratio of periventricular hyperintensities and deep white matter hyperintensities volumes to intracranial volumes, neuropsychological test scores and blood sample data in mild cognitive impairment patients

|                 | Coefficient PVH/DWMH | P-value |
|-----------------|-----------------------|---------|
| MMSE            | −0.18/−0.03           | 0.29/0.85|
| FAB             | −0.24/−0.09           | 0.15/0.60|
| TMT-A           | 0.53/0.21             | 0.001**/0.23|
| TMT- B          | 0.38/0.13             | 0.02*/0.44|
| WMS-R           | −0.06/0.10            | 0.72/0.54|
| VF              | −0.26/0.02            | 0.13/0.90|
| GDS-15          | 0.21/−0.10            | 0.21/0.57|
| Cystatin C      | 0.50/0.07             | 0.002**/0.69|
| 25(OH)VitD      | −0.07/−0.01           | 0.67/0.95|
| Homocysteine    | 0.27/−0.17            | 0.11/0.32|

25(OH)VitD, 25-hydroxyvitamin D; DWMH, deep white matter hyperintensities; FAB, Frontal Assessment Battery; GDS, Geriatric Depression Scale; MCI, mild cognitive impairment patients; MMSE, Mini-Mental State Examination; NC, normal control participants; PVH, periventricular hyperintensities; TMT, Trail Making Test; VF, Verbal fluency; WMS-R-Logical Memory (immediate), Wechsler Memory Scale-Revised-Logical Memory I. *P < 0.05, significant correlation between ratio of PVH or DWMH volume to ICV; **P < 0.005, significant correlation between ratio of PVH or DWMH volume to ICV.

Discussion

We found that patients with MCI showed greater PVH and DWMH volumes than normal controls, although the difference did not reach statistical significance. Many recent studies, including those carrying out autopsies, have reported the association between cerebrovascular disease and AD.16,17 Therefore, the present results that patients with MCI tend to have greater white matter abnormalities compared with NC were consistent with the previous reports. We observed that only the PVH volume : ICV ratio significantly correlated with TMT-AB scores in MCI. The association of WMH volume with attention and executive functions in the present study was consistent with the results of previous studies in MCI group.18 Furthermore, we observed that attention and executive dysfunction are likely to be associated more closely with PVH volume than DWMH volume in patients with MCI. Although the mechanisms of PVH remain unclear, PVH has been reported to be affected not only by medication, statins, antithrombotics and antihypertensives) in MCI by linear multiple regression analysis. The PVH volume : ICV ratio significantly correlated with only CysC level, whereas the DWMH volume : ICV ratio did not correlate with any items at all. Figure 1 shows that the PVH volume : ICV ratio has a statistically significant positive correlation with serum CysC level, whereas the DWMH volume : ICV ratio did not correlate with serum CysC level on Pearson’s analysis.

Table 3  Linear regression analyses for factors associated with the ratio of periventricular hyperintensities and deep white matter hyperintensities volume to intracranial volumes in mild cognitive impairment patients

| Independent variable | Ratio of PVH volume | Ratio of DWMH volume |
|----------------------|---------------------|-----------------------|
|                      | B                  | β                    | P-value | B              | β              | P-value |
| Sex                  | 0.143              | 0.119                | 0.775   | −0.129         | 0.231         | 0.617   |
| Age                  | 0.000              | −0.005               | 0.982   | −0.003         | 0.065         | 0.791   |
| AST                  | 0.016              | 0.338                | 0.461   | 0.01           | 0.451         | 0.377   |
| ALT                  | −0.014             | −0.209               | 0.65    | −0.02          | −0.648        | 0.219   |
| T-Chol               | −0.003             | −0.182               | 0.743   | −0.009         | −1.037        | 0.112   |
| LDL-Chol             | −0.005             | −0.236               | 0.574   | 0.007          | 0.664         | 0.169   |
| BUN                  | 0.000              | −0.003               | 0.992   | −0.017         | −0.272        | 0.415   |
| Cr                   | −1.957             | −0.858               | 0.276   | 0.85           | 0.797         | 0.355   |
| eGFR                 | −0.03              | −0.729               | 0.134   | 0.000          | 0.000         | 0.999   |
| Glu                  | −0.002             | −0.049               | 0.887   | 0.005          | 0.323         | 0.402   |
| HbA1c                | −0.119             | −0.089               | 0.832   | −0.009         | −0.014        | 0.975   |
| VitB12               | 0.000              | −0.18                | 0.38    | 0.000          | −0.094        | 0.673   |
| CysC                 | 2.807              | 1.095                | 0.016*  | 0.495          | 0.413         | 0.349   |
| 25(OH)VitD           | −0.013             | −0.264               | 0.238   | 0.008          | 0.37          | 0.143   |
| Homocysteine         | −0.05              | −0.307               | 0.378   | −0.031         | −0.414        | 0.286   |
| Hypertension         | 0.83               | 0.733                | 0.302   | 0.09           | 0.169         | 0.825   |
| Diabetes mellitus    | 0.33               | 0.219                | 0.588   | −0.412         | −0.582        | 0.21    |
| Hypercholesterolem   | −0.401             | −0.354               | 0.351   | −0.02          | −0.039        | 0.925   |
| Coronary artery disease | −0.309       | −0.125               | 0.567   | 0.154          | 0.134         | 0.58    |
| Antidiabetic medication | −0.108          | −0.044               | 0.875   | 0.626          | 0.543         | 0.102   |
| Statin               | −0.07              | −0.055               | 0.853   | 0.105          | 0.177         | 0.593   |
| Antithrombotics      | 0.528              | 0.258                | 0.297   | 0.382          | 0.4           | 0.155   |
| Antihypertensives    | −0.738             | −0.653               | 0.381   | −0.2           | −0.379        | 0.641   |

25(OH)VitD, 25-hydroxyvitamin D; ALT, alanine aminotransferase; AST, aspartate transaminase; BUN, blood urea nitrogen; Cr, creatinine; CysC, cystatin C; DWMH, deep white matter hyperintensities; FAB, Frontal Assessment Battery; eGFR, estimated glomerular filtration rate; Glu, glucose; HbA1c, hemoglobin A1c; LDL-Chol, low-density lipoprotein cholesterol; PVH, periventricular hyperintensities; T-Chol, total cholesterol; VitB12, vitamin B12. *P < 0.05, significant correlation between ratio of PVH or DWMH volume to ICV.
ischemic changes, but also by increased fluid accumulation and reduced integrity of the ventricular ependyma, which might be associated with blood–brain barrier breakdown. Montagne et al. recently reported that both patients with MCI and AD showed blood–brain barrier disruption in the hippocampus and some areas of the cortex and periventricular regions on neuroimaging. This might be one explanation for MCI patients showing larger PVH volumes, and PVH volumes being more closely associated with cognitive dysfunction compared with NC in the present study. Furthermore, the periventricular region has been reported to include functionally important cholinergic neural pathways, and PVH might exacerbate pre-existing cholinergic deficits, particularly in AD. The significant association between PVH and cognitive impairment, particularly attention and executive dysfunctions in patients with MCI in the present study, might be caused by cholinergic neural burden by PVH.

We found a significant positive correlation between PVH volume and serum CysC levels. CysC is a cysteine proteinase inhibitor that has been recognized as a marker for early renal impairment, which is more sensitive than creatinine for estimating glomerular filtration rate. It has been recognized that kidney dysfunction is a risk factor for white matter abnormalities. Although the association between WMH and kidney dysfunction have not been fully elucidated, particularly regarding subclinical vascular dysfunction, it is assumed that the cells of the kidney and brain are passively perfused throughout systole and diastole by pulsatile flow, whereas their smallest arteries are exposed to high pulsatile pressure by upstream vasodilation. There was a significant correlation between CysC levels and PVH volumes, but not DWMH volumes. Lee et al. recently showed that CysC level significantly correlated with total WMH volume. We also found a significant association between CysC level and total WMH volume, although we do not show the results. We believe that PVH volume might closely reflect total WMH burden more than DWMH volume, as seen with other studies. However, a significant correlation of CysC with PVH volume, but not with DWMH volume, might simply be owing to a larger range of volumes of PVH than DWMH, because we observed that the volume of PVH was larger than that of DWMH.

Linear regression analysis showed that CysC levels were significantly associated with ratios of PVH volume to ICV, which was independent of creatinine, estimated glomerular filtration rate and other parameters. CysC has been reported to be associated with various cerebrovascular complications, although the mechanisms are not fully understood. Umegae et al. reported that CysC is upregulated in regressive astrocytes in a self-defense response to the process of white matter degeneration in patients with WMH. Levy et al. showed that CysC colocalized with amyloid-beta in parenchymal and vascular amyloid deposits in AD patient brains. Furthermore, Sun et al. reported that CysC regulates soluble amyloid-beta levels and is subsequently associated with neuronal deficits in a mouse model of AD. Taking the aforementioned into account,

Figure 1 Scatter plots of correlations between cystatin C level and ratios of periventricular hyperintensities (PVH) and deep white matter hyperintensities (DWMH) volumes to intracranial volumes (ICV) in patients with mild cognitive impairment. (a) Ratios of PVH volume to ICV significantly correlated with cystatin C level in patients with mild cognitive impairment. (b) Ratios of DWMH volume to ICV did not significantly correlate with cystatin C levels in patients with mild cognitive impairment. R indicates correlation coefficients determined using Pearson’s analysis.
CysC might have more direct associations with pathological mechanisms of the brain than just renal impairment. The present study had some limitations. First, the analyses were based on data obtained at one point, namely, at the initial visit. Therefore, we are currently carrying out longitudinal analyses. Second, the number of participants in the NC group was very small. Therefore, it is possible that CysC is associated with white matter abnormalities in the NC group in addition to the MCI group, because the association between CysC and PVH volume were significantly positive in all participants, although we did not show the results. Third, we excluded individuals showing severe white matter diseases, so we should take caution in interpreting the results. Fourth, we did not assess the association between WMH volume of each region and cognitive dysfunction in the present study. Therefore, we are planning to investigate associations between regional WMH volumes and brain function using SPECT in the near future. Fifth, although the underlying pathology in MCI patients was not confirmed in the present study, neuroimaging data were used as part of the diagnostic process. In particular, decreases in regional cerebral blood flow in the parietotemporal association cortex on SPECT is recognized as a diagnostic pattern of MCI due to AD. Therefore, we feel confident that most cases in the present series of MCI did indeed have AD pathology.

In conclusion, PVH volume is closely associated with frontal lobe dysfunction, particularly with attention and executive dysfunction. Serum CysC level was associated with PVH volume, which suggests that CysC might be a useful marker for determining treatment strategies for white matter abnormalities in amnestic MCI.

Acknowledgements

This study was supported by JSPS KAKENHI (JP17K09327). We thank H Hirose and K Sasaki of the Department of Nuclear Medicine of Tokyo Medical University for their support and technical assistance. We are also grateful to the editors of the Department of International Medical Communications at Tokyo Medical University for reviewing the manuscript.

Disclosure statement

The authors declare no conflict of interest.

References

1 Birdsell AC, Kosciel RL, Jonaitis EM et al. Regional white matter hyperintensities: aging, Alzheimer’s disease risk, and cognitive function. Neuronal Aging 2014; 35: 769–776.
2 Krishnan KR, Goli V, Ellinwood EH, France RD, Blazer DG, Nemeroff CB. Leukoencephalopathy in patients diagnosed as major depressive. Biol Psychiatry 1988; 23: 519–522.
3 Tokuchi R, Hishikawa N, Kurata T et al. Clinical and demographic predictors of mild cognitive impairment for converting to Alzheimer’s disease and reverting to normal cognition. J Neuro Sci 2014; 346: 288–292.
4 van Straaten EC, Harvey D, Scheltens P et al. Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia. J Neuro Sci 2008; 255: 1302–1308.
5 Targosz-Gajnik M, Siuda J, Ochudlo S, Opala G. Cerebral white matter lesions in patients with dementia - from MCI to severe Alzheimer’s disease. J Neuro Sci 2009; 283: 79–82.
6 Lampe L, Kharabian-Masouleh S, Kynast J et al. Lesion location matters: the relationships between white matter hyperintensities on cognition in the healthy elderly. J Cereb Blood Flow Metab 2019; 39: 36–43.
7 Nakano K, Park K, Zheng R et al. Leukoaraisis significantly worsens driving performance of ordinary older drivers. PLoS One 2014; 9: e108333.
8 Wada M, Nagasawa H, Kawanami T et al. Cystatin C as an index of cerebral small vessel disease: results of a cross-sectional study in community-based Japanese elderly. Eur J Neurol 2010; 17: 383–390.
9 Prager JM, Thomas C, Ankenbrandt WJ et al. Association of white matter hyperintensities with low serum 25-hydroxyvitamin D levels. AJNR Am J Neuroradiol 2014; 35: 1145–1149.
10 Lee CC, Hsu SW, Huang CW et al. Effects of Homocysteine on white matter diffusion parameters in Alzheimer’s disease. BMC Neurol 2017; 17: 192.
11 Gerring DT, Nabavi A, Kikinis R et al. An integrated visualization system for surgical planning and guidance using image fusion and an open MR. J Magn Reson Imaging 2001; 13: 967–975.
12 Minoshima S, Frey KA, Koppel RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995; 36: 1238–1248.
13 Hirok K, Ohnishi T, Hirata Y et al. The prediction of rapid conversion to Alzheimer’s disease in mild cognitive impairment using regional cerebral blood flow SPECT. Neuroimage 2005; 28: 1014–1021.
14 Jack CR Jr, Albert MS, Knopman DS et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 257–262.
15 Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol 1987; 149: 351–356.
16 Beach TG, Wilson JR, Sue L et al. Circle of Willis arteriosclerosis: association with Alzheimer’s disease, neurotic plaques and neurofibrillary tangles. Acta Neuropathol 2007; 113: 13–21.
17 Yardehan M, Xie SX, Kling MA et al. Cerebrovascular arteriosclerosis correlates with Alzheimer pathology in neurodegenerative dementia. Brain 2012; 135Pt 12: 5749–5756.
18 Debette S, Bombois S, Bruandet A et al. Subcortical hyperintensities are associated with cognitive decline in patients with mild cognitive impairment. Stroke 2007; 38: 2924–2930.
19 Fernando MS, Simpson JE, Matthews F et al. White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hyperfusion injury. Stroke 2006; 37: 1391–1398.
20 Montagne A, Zhao Z, Zhokovic BV. Alzheimer’s disease: a matter of blood-brain barrier dysfunction? J Exp Med 2017; 214: 3151–3169.
21 Behl P, Bocci V, Swartz RH et al. Striatal subcortical hyperintensities in cholinergic pathways and executive function decline in treated Alzheimer patients. Arch Neurol 2007; 64: 266–272.
22 Bohnen NI, Bogan CW, Muller ML. Frontal and periventricular brain white matter lesions and cortical deafferentation of cholinergic and other neuromodulatory axonal projections. Eur Neurol 2009; 1: 33–50.
23 Coll E, Botey A, Alvarez L et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000; 36: 29–34.
24 Ikram MA, Vernooij MW, Hofman A, Niessen WJ, van der Lugt A, Breteler MM. Kidney function is related to cerebral small vessel disease. Stroke 2008; 39: 55–61.
25 O’Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension (Dallas, Tex) 1999; 33: 200–204.
26 Lee WJ, Jung KH, Ryu YJ et al. Cystatin C, a potential marker for cerebral microvascular compliance, is associated with white-matter hyperintensities progression. PLoS One 2017; 12: e0184999.
27 DeCarli C, Fletcher E, Ramey V, Harvey D, Jagust WJ. Anatomical mapping of white matter hyperintensities (WMH): exploring the relationships between periventricular WMH, deep WMH, and total WMH burden. Stroke 2005; 36: 50–55.
28 Umeo N, Nagai A, Terashima M et al. Cystatin C expression in ischemic white matter lesions. Acta Neurol Scand 2008; 118: 60–67.
29 Levy E, Sastre M, Kumar A et al. Codispofosition of cystatin C with amyloid-beta protein in the brain of Alzheimer disease patients. J Neuropath Exp Neurol 2001; 60: 94–104.
30 Sun B, Zhou Y, Halabisky B et al. Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer’s disease. Neurobiol 2008; 60: 247–257.

How to cite this article: Hirao K, Yamashita F, Tsugawa A, et al. Association of serum cystatin C with white matter abnormalities in patients with amnestic mild cognitive impairment. Geriatr. Gerontol. Int. 2019;19:1036–1040. https://doi.org/10.1111/ggi.13767